Correction to:*Scientific Reports* 10.1038/s41598-017-04735-0, published online 13 July 2017

This Article contains errors. In Figure 1, the images used for panels 1A-i, 1E-g, and 1E-i are incorrect. The corrected Figure [1](#Fig1){ref-type="fig"} appears below.Figure 1PAPPA promotes human endometrial cell receptivity. HEC-1A, Ishikawa and RL95-2 cell monolayers were differently pre-treated as indicated before CMFDA-stained JAR cells (green) were plated. (**A, C, E**) Attached JAR cells were photographed after 1 h under a fluorescenct microscope, **(B, D, F**), the respective adhesion rate was calculated as the percentage of attached JAR cells. (**A**) HEC-1A, Ishikawa and RL95-2 cells were pre-treated with different doses of rhPAPPA (1 ng/ml and 10 ng/ml) for 48 h. (**C**) HEC-1A cells were pre-incubated with non-pregnancy serum (NS) (a--c), pregnancy serum (PS) (d--f), and threatened abortion serum (TS) (g--i) in the absence (a, d, g), or presence of anti-PAPPA (b, e, h) and anti-PAPPA plus rhPAPPA (c, f, i). **(E)** HEC-1A cells were pre-incubated with conditional medium (CM) from JAR cells (a--c), CM after JAR cells were treated with progesterone (100 μM) (P4 CM) (d--f), CM after JAR cells were treated with progesterone (100 μM) plus RU486 (10 μM) (P4 + R CM) (g--i) in the absence (a, d, g), or presence of anti-PAPPA (b, e, h) and anti-PAPPA plus rhPAPPA (c, f, i) before JAR cells were added. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001. The bar represents 100 μm. The data were presented as the mean ± SEM of three independent experiments.
